Investigations Against AstraZeneca Employees in China

The pharmaceutical company AstraZeneca has confirmed that a "small number" of its employees in China are under investigation. This confirmation follows a Bloomberg report on Thursday, which stated that the Chinese police are investigating five current and former AstraZeneca employees for violations of data protection laws and importing an unapproved drug. AstraZeneca did not provide further comments on the ongoing investigations. According to Bloomberg, the employees in question are Chinese nationals who marketed cancer drugs for AstraZeneca and are now under scrutiny by authorities for collecting patient data and distributing an unapproved medication. The company has a significant presence in China and has already invested in developing independent supply chains within the country. In 2023, revenue in China amounted to 5.9 billion dollars, representing 13 percent of the total revenue.